Yamada K - Search Results

1

MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma.

Yokomizo R, Yanaihara N, Yamaguchi N, Saito M, Kawabata A, Takahashi K, Takenaka M, Yamada K, Shapiro JS, Okamoto A. Yokomizo R, et al. Among authors: yamada k. Oncotarget. 2019 Aug 6;10(47):4880-4893. doi: 10.18632/oncotarget.27117. eCollection 2019 Aug 6. Oncotarget. 2019. PMID: 31448054 Free PMC article.

2

[Molecular genetics of ovarian cancer].

Yanaihara N, Okamoto A, Takakura S, Yamada K, Ochiai K, Tanaka T. Yanaihara N, et al. Among authors: yamada k. Nihon Rinsho. 2004 Oct;62 Suppl 10:441-8. Nihon Rinsho. 2004. PMID: 15535284 Review. Japanese. No abstract available.

3

[Overview of key genes implicated in ovarian carcinogenesis].

Yamada K, Ueda K, Yanaihara N, Motegi M, Okamoto A, Ochiai K, Tanaka T. Yamada K, et al. Nihon Rinsho. 2004 Oct;62 Suppl 10:454-7. Nihon Rinsho. 2004. PMID: 15535286 Review. Japanese. No abstract available.

4

Frequent apoptosis in placental villi from pregnancies complicated with intrauterine growth restriction and without maternal symptoms.

Endo H, Okamoto A, Yamada K, Nikaido T, Tanaka T. Endo H, et al. Among authors: yamada k. Int J Mol Med. 2005 Jul;16(1):79-84. Int J Mol Med. 2005. PMID: 15942681

5

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.

Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, Ishii N, Yanaihara N, Yamada K, Takikawa O, Kawaguchi R, Isonishi S, Tanaka T, Urashima M. Okamoto A, et al. Among authors: yamada k. Clin Cancer Res. 2005 Aug 15;11(16):6030-9. doi: 10.1158/1078-0432.CCR-04-2671. Clin Cancer Res. 2005. PMID: 16115948

6

Nonpuerperal inversion of the uterus associated with endometrial cancer: a case report.

Ueda K, Okamoto A, Yamada K, Saito M, Takakura S, Tanaka T, Ochiai K. Ueda K, et al. Among authors: yamada k. Int J Clin Oncol. 2006 Apr;11(2):153-5. doi: 10.1007/s10147-005-0544-3. Int J Clin Oncol. 2006. PMID: 16622752

7

Association of extracellular matrix metalloproteinase inducer in endometrial carcinoma with patient outcomes and clinicopathogenesis using monoclonal antibody 12C3.

Ueda K, Yamada K, Urashima M, Ishibashi Y, Shirai M, Nikaido T, Takahashi H, Okamoto A, Saito M, Yasuda M, Ohkawa K, Tanaka T. Ueda K, et al. Among authors: yamada k. Oncol Rep. 2007 Apr;17(4):731-5. Oncol Rep. 2007. PMID: 17342307

8

Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.

Takakura S, Saito M, Ueda K, Motegi M, Takao M, Yamada K, Okamoto A, Niimi S, Sasaki H, Tanaka T, Ochiai K. Takakura S, et al. Among authors: yamada k. Int Surg. 2007 Jul-Aug;92(4):202-8. Int Surg. 2007. PMID: 18050828

9

Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma.

Iida Y, Aoki K, Asakura T, Ueda K, Yanaihara N, Takakura S, Yamada K, Okamoto A, Tanaka T, Ohkawa K. Iida Y, et al. Among authors: yamada k. Int J Oncol. 2012 Jun;40(6):2122-30. doi: 10.3892/ijo.2012.1406. Epub 2012 Mar 19. Int J Oncol. 2012. PMID: 22447231

10

Pilot study of CD147 protein expression in epithelial ovarian cancer using monoclonal antibody 12C3.

Ueda K, Yamada K, Kiyokawa T, Iida Y, Nagata C, Hamada T, Saito M, Aoki K, Yanaihara N, Takakura S, Okamoto A, Ochiai K, Ohkawa K, Tanaka T. Ueda K, et al. Among authors: yamada k. J Obstet Gynaecol Res. 2012 Sep;38(9):1211-9. doi: 10.1111/j.1447-0756.2012.01853.x. Epub 2012 May 8. J Obstet Gynaecol Res. 2012. PMID: 22563698

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,266 results

Search Page

Filters